Cayman’s Renin Inhibitor Screening Assay provides a convenient assay in a 96-well format for evaluating human renin inhibitors. The assay utilizes a renin-based synthetic peptide substrate which incorporates the fluorophore EDANS at one end and an EDAN-quenching molecule (Dabcyl) at the other end. After cleavage by renin, the peptide-EDANS product is released yielding bright fluorescence which can be easily analyzed using excitation wavelengths between 335-345 nm and emission wavelengths between 485-510 nm.